Microfluidic particle dam for direct visualization of SARS-CoV-2 antibody levels in COVID-19 vaccinees.
Minghui WuSiying WuGaobo WangWengang LiuLok Ting ChuTianyi JiangHoi Kwan KwongHiu Lam ChowIris Wai Sum LiTing-Hsuan ChenPublished in: Science advances (2022)
Various COVID-19 vaccines are currently deployed, but their immunization varies and decays with time. Antibody level is a potent correlate to immune protection, but its quantitation relies on intensive laboratory techniques. Here, we report a decentralized, instrument-free microfluidic device that directly visualizes SARS-CoV-2 antibody levels. Magnetic microparticles (MMPs) and polystyrene microparticles (PMPs) can bind to SARS-CoV-2 antibodies simultaneously. In a microfluidic chip, this binding reduces the incidence of free PMPs escaping from magnetic separation and shortens PMP accumulation length at a particle dam. This visual quantitative result enables use in either sensitive mode [limit of detection (LOD): 13.3 ng/ml; sample-to-answer time: 70 min] or rapid mode (LOD: 57.8 ng/ml; sample-to-answer time: 20 min) and closely agrees with the gold standard enzyme-linked immunosorbent assay. Trials on 91 vaccinees revealed higher antibody levels in mRNA vaccinees than in inactivated vaccinees and their decay in 45 days, demonstrating the need for point-of-care devices to monitor immune protection.
Keyphrases
- sars cov
- high throughput
- circulating tumor cells
- single cell
- respiratory syndrome coronavirus
- label free
- coronavirus disease
- loop mediated isothermal amplification
- ms ms
- molecularly imprinted
- liquid chromatography
- mass spectrometry
- binding protein
- high resolution
- liquid chromatography tandem mass spectrometry
- solid phase extraction
- anti inflammatory